SALBUMOL (salbutamol), beta-2 agonist – labour inhibitor
TRANSPARENCY COMMITTEE OPINION
Opinions on drugs -
Posted on
Aug 29 2018
Reason for request
Renewal of inclusion
Insufficient clinical benefit to justify its reimbursement in the short-term treatment of uncomplicated preterm labour and in emergency use in specific obstetric scenarios due to potentially severe maternal adverse cardiopulmonary effects
-
SALBUMOL has MA for the short-term treatment of uncomplicated premature labour and for emergency use in specific obstetric scenarios.
-
Betamimetic tocolytics are not recommended due to the existence of potentially severe maternal adverse cardiopulmonary effects.
-
SALBUMOL no longer has a role in the therapeutic strategy
Clinical Benefit
Insufficient |
- |